4 March 2020 - - Indian drugmaker Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) said it has undertaken the first-to-market launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets, a therapeutic equivalent generic version of Vimovo (Naproxen and Esomeprazole Magnesium) Delayed-Release Tablets approved by the US Food and Drug Administration (USFDA), the company said.

The Vimovo (Naproxen and Esomeprazole Magnesium) Delayed-Release Tablets brand had US sales of approximately USD414 m MAT for the most recent twelve months ending in December 2019 according to IQVIA Health.

Dr. Reddy's Naproxen and Esomeprazole Magnesium Delayed-Release Tablets are available in 375 mg/20 mg and 500 mg/20 mg tablets in bottle count sizes of 60.

Dr. Reddy's Laboratories, through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products, offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Its major markets include USA, India, Russia and CIS countries, and Europe.